EUROEYES (01846) announced that on September 2, 2025 (after trading hours), the company's wholly-owned subsidiary EuroEyes Swiss (as purchaser), the company (as guarantor), and Betterview Swiss (as vendor) entered into a Swiss agreement, whereby EuroEyes Swiss agreed to purchase Swiss assets from Betterview Swiss for a total Swiss consideration of 12.01 million Swiss francs (equivalent to approximately HK$117 million).

On September 2, 2025 (after trading hours), the company's wholly-owned subsidiary EuroEyes UK (as purchaser) and Betterview UK (as vendor) entered into a UK agreement, whereby EuroEyes UK agreed to purchase and Betterview UK agreed to sell UK assets for a total UK consideration of 200,000 Swiss francs (equivalent to approximately £184,442 and HK$1.949 million).

The Swiss assets include (i) seven refractive surgery medical clinics located in Zurich, Bern, Lucerne, St. Gallen, Lugano, Lausanne, and Geneva; (ii) refractive surgery treatment operating rooms located in Zurich; and (iii) certain headquarters assets under the Swiss agreement, which will include related: (a) commercial contracts, customer contracts, employment contracts, lease contracts, and past patient agreements (except those agreed to be retained by Betterview Swiss); (b) leasehold improvements, furniture and fixtures, office equipment, medical machinery/production equipment, tools, computer hardware and software; (c) intellectual property rights; (d) customer data; (e) personnel files, technical, operational and marketing records, manuals and guidelines; (f) liabilities under the contracts mentioned in (a) above, excluding those past patient agreements agreed to be retained by Betterview Swiss.

The UK assets comprise the property, assets and rights used by Betterview UK in the UK business (excluding certain business debts, cash on hand or in banks, and any amounts recoverable by Betterview UK for taxes related to the UK business), where the UK business refers to the ophthalmic services business (including but not limited to laser treatment and refractive surgery) operated by Betterview UK under the names "Betterview" or "Betterview Britain."

The announcement stated that the group is primarily engaged in the refractive surgery business. The acquisitions will enable the group to immediately establish business presence in major Swiss cities and consolidate its position in London (one of the major European refractive surgery markets). The clinics comprising the assets have generated recurring revenue and possess a solid customer base.

The board believes that the acquisitions represent a strategic expansion by the group into Switzerland, an important European market, and consolidate its market position in the UK, thereby expanding the group's geographical business distribution and are expected to contribute positively to the group's long-term growth. The directors believe that the terms of the agreements are fair and reasonable, and the acquisitions are in the overall interests of the company and its shareholders.